MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Ra Medical Systems Cost of Revenue 2011-2026 | RMED
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Ra Medical Systems
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 K | 42 K | 161 K | 1.56 M | 5.48 M | 8.85 M | 4.21 M | 4.16 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.85 M | 42 K | 3.07 M |
Quarterly Cost of Revenue Ra Medical Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 K | 14 K | 11 K | - | 10 K | 16 K | 5 K | - | 6 K | 7 K | 10 K | - | 161 K | 66 K | 95 K | - | 246 K | 520 K | 1.37 M | - | 1.42 M | 1.17 M | 1.58 M | - | 2.42 M | 2.73 M | 1.94 M | - | 1.28 M | 990 K | 736 K | - | 693 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.73 M | 5 K | 701 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
1.2 B | $ 173.14 | -0.8 % | $ 13 B |  USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 279.25 | 0.63 % | $ 7.88 B | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 10.9 | -1.54 % | $ 1.64 B | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.17 | -0.41 % | $ 1.64 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | 0.84 % | $ 38 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.3 | -1.79 % | $ 124 M |  France |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 37.59 | -1.03 % | $ 5.6 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 61.79 | 0.83 % | $ 91.5 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.89 | - | $ 1.15 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.0 | -3.86 % | $ 16.9 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 8.68 | -3.12 % | $ 246 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.12 | -1.19 % | $ 204 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.97 | 0.19 % | $ 375 M | USA |
 |
Inogen
INGN
|
194 M | $ 6.33 | -4.95 % | $ 168 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 62.78 | -0.93 % | $ 3.42 B |  Britain |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.7 | 4.4 % | $ 68.2 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
958 M | $ 90.42 | -1.07 % | $ 12.2 B | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.11 | -0.96 % | $ 870 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.04 | 1.62 % | $ 360 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.69 | -1.43 % | $ 28.9 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 54.02 | -4.71 % | $ 1.59 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.74 | -0.51 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 85.11 | -1.8 % | $ 2.96 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 77.87 | -1.62 % | $ 45.5 B | USA |